Switzerland-based pharmaceutical and healthcare company Novartis will pay nearly $347 million in combined criminal and civil penalty settlements with U.S. authorities announced Thursday to resolve all Foreign Corrupt Practices Act investigations into historical conduct by the company and its subsidiaries.
